🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Australia / NCT05280340
Unknown Phase 1/2

Anakinra for Preterm Infants Pilot

NCT05280340 · tracked via the Priya Life Science Australia tracker
Sponsor
Monash Medical Centre
Phase
Phase 1/2
Started
2022-02-15
Last updated
2024-09-19

Condition(s) studied

Prematurity; ExtremeInflammation

Investigational drug(s) / intervention(s)

Anakinra →

Anakinra: Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.

Study summary

Phase I/II study of anakinra to prevent the impact of perinatal inflammation in extremely premature infants.

Eligibility

Sex
ALL
Min age
24 Weeks
Max age
28 Weeks
Healthy volunteers
No
Inclusion Criteria: * Born at 24 to 27+6 weeks gestation Exclusion Criteria: * Inability of the legal representatives to consent * Any disease or condition that the investigators judge could confound the trial results; these include, but are not limited to, genetic syndromes, severe cardiac abnormalities, substantial pre-/perinatal compromise (profound/severe hypoxia (SaO2 \<80% for \>3h), congenital diaphragmatic hernia, intrauterine stroke and others. * Imminent death

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Monash Health Clayton Victoria
Starship Children's Hospital, Te Whatu Ora - Health New Zealand Grafton Auckland

On this site

📄 Kineret (anakinra) drug profile →

More Monash Medical Centre trials in Australia

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05280340 on ClinicalTrials.gov ↗ ← All trials in Australia